{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:31:30Z","timestamp":1683876690025},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Trop Med Rep"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s40475-019-00174-1","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:54:29Z","timestamp":1554375269000},"page":"50-54","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibody Immunity and Natural Resistance to Cryptococcosis"],"prefix":"10.1007","volume":"6","author":[{"given":"Nuria","family":"Trevijano-Contador","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liise-anne","family":"Pirofski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"174_CR1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/mmy.38.5.379.383","volume":"38","author":"MS Lazera","year":"2000","unstructured":"Lazera MS, Salmito Cavalcanti MA, Londero AT, Trilles L, Nishikawa MM, Wanke B. Possible primary ecological niche of Cryptococcus neoformans. Med Mycol. 2000;38:379\u201383.","journal-title":"Med Mycol"},{"key":"174_CR2","doi-asserted-by":"crossref","DOI":"10.1128\/9781555818241","volume-title":"Cryptococcus neoformans","author":"A Casadevall","year":"1998","unstructured":"Casadevall A, Perfect J. Cryptococcus neoformans. Washington DC: ASM; 1998."},{"key":"174_CR3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/fmb.14.132","volume":"10","author":"S Rohatgi","year":"2015","unstructured":"Rohatgi S, Pirofski LA. Host immunity to Cryptococcus neoformans. Future Microbiol. 2015;10:565\u201381.","journal-title":"Future Microbiol"},{"key":"174_CR4","doi-asserted-by":"crossref","unstructured":"Pirofski LA, Casadevall A. Immune-mediated damage completes the parabola: Cryptococcus neoformans pathogenesis can reflect the outcome of a weak or strong immune response. mBio. 2017;8.","DOI":"10.1128\/mBio.02063-17"},{"key":"174_CR5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"\u2022 Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873\u201381 Provides a circa 2014 estimate of the global incidence of HIV-associated cryptococcal disease, HIV incidence, ART access, and retention in care using published UNAIDS and cryptococcal prevalence data.","journal-title":"Lancet Infect Dis"},{"key":"174_CR6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0956462417732649","volume":"29","author":"AA Shaheen","year":"2018","unstructured":"Shaheen AA, Somayaji R, Myers R, Mody CH. Epidemiology and trends of cryptococcosis in the United States from 2000 to 2007: a population-based study. Int J STD AIDS. 2018;29:453\u201360.","journal-title":"Int J STD AIDS"},{"key":"174_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","volume":"1508","author":"DA Enoch","year":"2017","unstructured":"Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17\u201365.","journal-title":"Methods Mol Biol"},{"key":"174_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/IAI.26.1.1-3.1979","volume":"26","author":"DP Monga","year":"1979","unstructured":"Monga DP, Kumar R, Mohapatra LN, Malaviya AN. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect Immun. 1979;26:1\u20133.","journal-title":"Infect Immun"},{"key":"174_CR9","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.4049\/jimmunol.174.12.8017","volume":"174","author":"J Rivera","year":"2005","unstructured":"Rivera J, Casadevall A. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunol. 2005;174:8017\u201326.","journal-title":"J Immunol"},{"key":"174_CR10","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1128\/IAI.70.3.1571-1580.2002","volume":"70","author":"M Feldmesser","year":"2002","unstructured":"Feldmesser M, Mednick A, Casadevall A. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect Immun. 2002;70:1571\u201380.","journal-title":"Infect Immun"},{"key":"174_CR11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1567-1364.2006.00073.x","volume":"6","author":"K Datta","year":"2006","unstructured":"Datta K, Pirofski LA. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 2006;6:525\u201336.","journal-title":"FEMS Yeast Res"},{"key":"174_CR12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566524054022567","volume":"5","author":"A Casadevall","year":"2005","unstructured":"Casadevall A, Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr Mol Med. 2005;5:421\u201333.","journal-title":"Curr Mol Med"},{"key":"174_CR13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/IAI.65.2.525-530.1997","volume":"65","author":"KM Aguirre","year":"1997","unstructured":"Aguirre KM, Johnson LL. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect Immun. 1997;65:525\u201330.","journal-title":"Infect Immun"},{"key":"174_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nri2524","volume":"9","author":"S Moir","year":"2009","unstructured":"Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9:235\u201345.","journal-title":"Nat Rev Immunol"},{"key":"174_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.155.1.333","volume":"155","author":"HC Lane","year":"1982","unstructured":"Lane HC, Shelhamer JH, Mostowski HS, Fauci AS. Human monoclonal anti-keyhole limpet hemocyanin antibody-secreting hybridoma produced from peripheral blood B lymphocytes of a keyhole limpet hemocyanin-immune individual. J Exp Med. 1982;155:333\u20138.","journal-title":"J Exp Med"},{"key":"174_CR16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/21505594.2017.1370529","volume":"9","author":"C Dufaud","year":"2018","unstructured":"\u2022\u2022 Dufaud C, Rivera J, Rohatgi S, Pirofski LA. Naive B cells reduce fungal dissemination in Cryptococcus neoformans infected Rag1(-\/-) mice. Virulence. 2018;9:173\u201384 This article establishes that B cells are able to reduce early Cn dissemination in mice and suggest that normal mouse IgM may be a key mediator of early antifungal immunity in the lungs.","journal-title":"Virulence"},{"key":"174_CR17","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.4049\/jimmunol.1201514","volume":"189","author":"S Rohatgi","year":"2012","unstructured":"Rohatgi S, Pirofski LA. Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J Immunol. 2012;189:5820\u201330.","journal-title":"J Immunol"},{"key":"174_CR18","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.4049\/jimmunol.0901638","volume":"184","author":"KS Subramaniam","year":"2010","unstructured":"\u2022 Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol. 2010;184:5755\u201367 This paper shows that presence of normal mouse IgM reduces Cn dissemination to the brain, promotes containment of Cn in the lungs, and enhances the phagocytic capacity of alveolar macrophages.","journal-title":"J Immunol"},{"key":"174_CR19","doi-asserted-by":"crossref","first-page":"e00265","DOI":"10.1128\/mBio.00265-13","volume":"4","author":"WA Szymczak","year":"2013","unstructured":"\u2022 Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski LA. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. mBio. 2013;4:e00265\u201313 This paper shows that XID mice, which lack B-1 cells and IgM, exhibit a dissemination phenotype whereby Cn disseminates from lungs to brain, and suggests that absence of IgM impairs Cn phagocytosis and allows Cn enlargment in the lungs.","journal-title":"mBio"},{"key":"174_CR20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.8332901","volume":"261","author":"DJ Rawlings","year":"1993","unstructured":"Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, et al. Mutation of unique region of Bruton\u2019s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358\u201361.","journal-title":"Science"},{"key":"174_CR21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.semcdb.2016.04.008","volume":"57","author":"N Trevijano-Contador","year":"2016","unstructured":"Trevijano-Contador N, Rueda C, Zaragoza O. Fungal morphogenetic changes inside the mammalian host. Semin Cell Dev Biol. 2016;57:100\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"174_CR22","doi-asserted-by":"crossref","first-page":"e1007007","DOI":"10.1371\/journal.ppat.1007007","volume":"14","author":"N Trevijano-Contador","year":"2018","unstructured":"\u2022 Trevijano-Contador N, de Oliveira HC, Garcia-Rodas R, Rossi SA, Llorente I, Zaballos A, et al. Cryptococcus neoformans can form titan-like cells in vitro in response to multiple signals. PLoS Pathog. 2018;14:e1007007 Provides a new method to investigate Titan cell formation in vitro. This method will make it posible to examine the effect of antibodies on Cn Titan cell formation.","journal-title":"PLoS Pathog"},{"key":"174_CR23","doi-asserted-by":"crossref","first-page":"e1000945","DOI":"10.1371\/journal.ppat.1000945","volume":"6","author":"O Zaragoza","year":"2010","unstructured":"Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. Fungal cell gigantism during mammalian infection. PLoS Pathog. 2010;6:e1000945.","journal-title":"PLoS Pathog"},{"key":"174_CR24","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/EC.05179-11","volume":"10","author":"LH Okagaki","year":"2011","unstructured":"Okagaki LH, Wang Y, Ballou ER, O'Meara TR, Bahn YS, Alspaugh JA, et al. Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. Eukaryot Cell. 2011;10:1306\u201316.","journal-title":"Eukaryot Cell"},{"key":"174_CR25","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1084\/jem.20100034","volume":"207","author":"RR Rapaka","year":"2010","unstructured":"Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, Zheng M, et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med. 2010;207:2907\u201319.","journal-title":"J Exp Med"},{"key":"174_CR26","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1128\/IAI.00278-07","volume":"75","author":"A Rachini","year":"2007","unstructured":"\u2022 Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun. 2007;75:5085\u201394.","journal-title":"Infect Immun"},{"key":"174_CR27","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/315102","volume":"180","author":"R Fleuridor","year":"1999","unstructured":"Fleuridor R, Lyles RH, Pirofski L. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis. 1999;180:1526\u201335.","journal-title":"J Infect Dis"},{"key":"174_CR28","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1128\/CDLI.12.10.1168-1176.2005","volume":"12","author":"K Subramaniam","year":"2005","unstructured":"Subramaniam K, French N, Pirofski LA. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. Clin Diagn Lab Immunol. 2005;12:1168\u201376.","journal-title":"Clin Diagn Lab Immunol"},{"key":"174_CR29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2249.1995.tb05568.x","volume":"99","author":"M Deshaw","year":"1995","unstructured":"Deshaw M, Pirofski LA. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Clin Exp Immunol. 1995;99:425\u201332.","journal-title":"Clin Exp Immunol"},{"key":"174_CR30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1086\/314953","volume":"180","author":"J Abadi","year":"1999","unstructured":"Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J Infect Dis. 1999;180:915\u20139.","journal-title":"J Infect Dis"},{"key":"174_CR31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1086\/599318","volume":"200","author":"K Subramaniam","year":"2009","unstructured":"\u2022\u2022 Subramaniam K, Metzger B, Hanau LH, Guh A, Rucker L, Badri S, et al. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis. 2009;200:244\u201351 This paper shows that in a prospective and a retrospective cohort, levels of IgM memory B cells were lower in HIV-infected persons with than without a history of CM, suggesting the hypothesis that reduced levels of IgM memory B cells may portend risk for development of CM.","journal-title":"J Infect Dis"},{"key":"174_CR32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CVI.00139-06","volume":"13","author":"Z Jalali","year":"2006","unstructured":"Jalali Z, Ng L, Singh N, Pirofski LA. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Clin Vaccine Immunol. 2006;13:740\u20136.","journal-title":"Clin Vaccine Immunol"},{"key":"174_CR33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.0105-2896.2004.0109.x","volume":"197","author":"R Carsetti","year":"2004","unstructured":"Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179\u201391.","journal-title":"Immunol Rev"},{"key":"174_CR34","doi-asserted-by":"crossref","first-page":"ofx255","DOI":"10.1093\/ofid\/ofx255","volume":"5","author":"S Rohatgi","year":"2018","unstructured":"\u2022\u2022 Rohatgi S, Nakouzi A, Carreno LJ, Slosar-Cheah M, Kuniholm MH, Wang T, et al. Antibody and B cell subset perturbations in human immunodeficiency virus-uninfected patients with cryptococcosis. Open Forum Infect Dis. 2018;5:ofx255.","journal-title":"Open Forum Infect Dis"},{"key":"174_CR35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3346\/jkms.2002.17.1.116","volume":"17","author":"EK Jo","year":"2002","unstructured":"Jo EK, Kim HS, Lee MY, Iseki M, Lee JH, Song CH, et al. X-linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections: the first case with molecular diagnosis in Korea. J Korean Med Sci. 2002;17:116\u201320.","journal-title":"J Korean Med Sci"},{"key":"174_CR36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","volume":"361","author":"D Vetrie","year":"1993","unstructured":"Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226\u201333.","journal-title":"Nature"},{"key":"174_CR37","first-page":"27","volume":"21","author":"B Arthurs","year":"2017","unstructured":"Arthurs B, Wunderle K, Hsu M, Kim S. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep. 2017;21:27\u20139.","journal-title":"Respir Med Case Rep"},{"key":"174_CR38","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","volume":"58","author":"M Baron","year":"2017","unstructured":"Baron M, Zini JM, Challan Belval T, Vignon M, Denis B, Alanio A, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;58:2981\u20132.","journal-title":"Leuk Lymphoma"},{"key":"174_CR39","first-page":"1593","volume":"374","author":"R Ruchlemer","year":"2016","unstructured":"Ruchlemer R, Ben Ami R, Lachish T. Ibrutinib for chronic lymphocytic leukemia. N Engl J Med. 2016;374:1593\u20134.","journal-title":"N Engl J Med"},{"key":"174_CR40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","volume":"66","author":"G Chamilos","year":"2018","unstructured":"Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with Ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018;66:140\u20138.","journal-title":"Clin Infect Dis"},{"key":"174_CR41","doi-asserted-by":"crossref","first-page":"ofw261","DOI":"10.1093\/ofid\/ofw261","volume":"4","author":"JA Messina","year":"2017","unstructured":"Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated Cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis. 2017;4:ofw261.","journal-title":"Open Forum Infect Dis"},{"key":"174_CR42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.vaccine.2008.11.030","volume":"27","author":"P Chiani","year":"2009","unstructured":"Chiani P, Bromuro C, Cassone A, Torosantucci A. Anti-beta-glucan antibodies in healthy human subjects. Vaccine. 2009;27:513\u20139.","journal-title":"Vaccine"},{"key":"174_CR43","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1128\/IAI.68.12.7049-7060.2000","volume":"68","author":"ML Rodrigues","year":"2000","unstructured":"Rodrigues ML, Travassos LR, Miranda KR, Franzen AJ, Rozental S, de Souza W, et al. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun. 2000;68:7049\u201360.","journal-title":"Infect Immun"},{"key":"174_CR44","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Yoon HA, Nakouzi A, Chang CC, Kuniholm MH, Carreno LJ, Wang T, et al. Association between plasma antibody responses and risk for Cryptococcus-associated immune reconstitution inflammatory syndrome. J Infect Dis. 2018; This study shows plasma antibody profiles differ in HIV-infected patients with and without cryptococcal immune reconstitution inflammatory syndrome (C-IRIS), and that levels of of IgM, Lam-IgM, Lam-IgG, and\/or GXM-IgM are lower in patients with than without C-IRIS, suggesting these antibodies may play a role in controlling C-IRIS\u2013associated inflammation.","DOI":"10.1093\/infdis\/jiy447"},{"key":"174_CR45","doi-asserted-by":"crossref","first-page":"ofy333","DOI":"10.1093\/ofid\/ofy333","volume":"6","author":"A Hlupeni","year":"2019","unstructured":"Hlupeni A, Nakouzi A, Wang T, Boyd KF, Makadzange TA, Ndhlovu CE, et al. Antibody responses in HIV-infected patients with advanced immunosuppression and asymptomatic cryptococcal antigenemia. Open Forum Infect Dis. 2019;6:ofy333.","journal-title":"Open Forum Infect Dis"},{"key":"174_CR46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cid\/civ936","volume":"62","author":"N Longley","year":"2016","unstructured":"Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, et al. Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin Infect Dis. 2016;62:581\u20137.","journal-title":"Clin Infect Dis"},{"key":"174_CR47","doi-asserted-by":"crossref","first-page":"ofu105","DOI":"10.1093\/ofid\/ofu105","volume":"1","author":"J Rhein","year":"2014","unstructured":"Rhein J, Bahr NC, Morawski BM, Schutz C, Zhang Y, Finkelman M, et al. Detection of high cerebrospinal fluid levels of (1-->3)-beta-d-glucan in cryptococcal meningitis. Open Forum Infect Dis. 2014;1:ofu105.","journal-title":"Open Forum Infect Dis"}],"container-title":["Current Tropical Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40475-019-00174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40475-019-00174-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40475-019-00174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T06:13:19Z","timestamp":1621663999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40475-019-00174-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s40475-019-00174-1","relation":{},"ISSN":["2196-3045"],"issn-type":[{"value":"2196-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nuria Trevijano-Contador and Liise-anne Pirofski declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}